Notably, we did not observe changes in the expression of type I IFNs in B cells of patients with SLE nor a difference in IFN expression in B cells or other PBMC subsets prior to and after CD19 CAR T cell therapy (data not shown). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.